Christian Neubauer & Antonia Riva-Frizberg | Co-Founders, Lumetry Diagnostics GmbH
Competition Sponsor: EIT Health of the European Union
Awardee Year: 2024
Lumetry Diagnostics is revolutionizing care for chronic lung disease with its innovative AI-driven breath analysis platform. Respiratory diseases, especially COPD— the third leading cause of death globally—affect over 900 million people annually. In Europe, 36.6 million individuals suffer from COPD, resulting in healthcare costs exceeding €38.6 billion due to hospitalizations and lost productivity. Existing diagnostic methods, such as spirometry and invasive blood gas analysis, are uncomfortable, exhausting and need training. Many patients, particularly those with severe conditions, experience significant diagnostic delays that impact their quality of life. Lumetry’s platform provides a non-invasive alternative. By monitoring pCO2 levels, Lumetry will enable early detection of lung diseases and hypercapnic attacks through simple breath analysis. Patients only need to breathe naturally while the AI analyzes biomarkers in their breath, reducing the need for invasive procedures and forced exhalation. Targeted at clinics, physicians, and pharmacies, Lumetry aims to reduce diagnostic costs and improves accessibility to high-quality respiratory care. As the company scales, it aims to expand into direct-to-consumer markets, empowering patients to monitor their respiratory health from home, facilitating early interventions, and improving long-term outcomes. By transforming the way lung diseases are screened and monitored, Lumetry Diagnostics is making respiratory care more accessible, efficient, and patient-friendly, helping millions to live better lives.